Dr. Reddy’s Laboratories has reported an impressive surge in its consolidated net profit for the March quarter, reflecting a robust 21% year-on-year increase to ₹1,587 crore. This remarkable growth, driven by strong sales across various regions—including the U.S. and India—marks a significant rise from the ₹1,307 crore net profit recorded in the same period last year.

Strong Revenue Growth

The Hyderabad-based pharmaceutical giant revealed in a recent regulatory filing that its revenue soared to ₹8,506 crore, compared to ₹7,083 crore in the previous year. This positive trend underscores the company’s effective strategies and market presence.

• Net Profit for FY25: ₹5,724 crore (up from ₹5,568 crore in FY24)
• Annual Revenue: ₹32,553 crore (compared to ₹27,916 crore in FY24)

Strategic Business Performance

G.V. Prasad, Co-Chairman and Managing Director of Dr. Reddy’s Laboratories, attributed this success to double-digit growth across all business sectors. He emphasized that the company’s advancements stem from:

• Successful product launches
• Increased revenues from pivotal products in the U.S.
• Effective integration of the recently acquired NRT business

Prasad also highlighted the firm’s commitment to enhancing its core operations through strategic portfolio management and partnerships, as well as exploring inorganic growth opportunities.

Regional Revenue Highlights

The report detailed impressive revenue figures from key markets:

• North America: Revenue climbed to ₹14,516 crore, a 12% increase from ₹12,989 crore in FY24.
• India Generics: Revenue rose to ₹5,373 crore, reflecting a 16% growth compared to ₹4,641 crore in the prior fiscal year.

Final Dividend Recommendation

In addition to these financial highlights, Dr. Reddy’s Laboratories has proposed a final dividend of ₹8 per share for the financial year 2024-25, reaffirming its commitment to rewarding shareholders.

The board has also approved the reappointment of G.V. Prasad as a whole-time director, with a designation as Co-Chairman and Managing Director for a five-year term starting from January 30, 2026.

Market Response

Following the announcement, shares of Dr. Reddy’s Laboratories experienced a slight increase, closing 0.67% higher at ₹1,156.40 on the BSE, reflecting investor confidence in the company’s growth trajectory.

In summary, Dr. Reddy’s Laboratories showcases a strong performance marked by significant profit growth and strategic initiatives aimed at solidifying its market position. With a focus on innovation and expansion, the company is well-positioned for future success in the pharmaceutical landscape.